Franklin FTSE South Korea ETF vs ResMed Inc. — how do they compare? Franklin FTSE South Korea ETF trades at $58.12 (market cap $1.88B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: ResMed Inc. is far larger — about 16.9× Franklin FTSE South Korea ETF's market cap, and ResMed Inc. pays a 1.17% dividend while Franklin FTSE South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 15 Days and ResMed Inc. for 51 Days on average.
| FLKR | RMD | |
|---|---|---|
Market Cap | $1.88B | $31.78B |
Volume | 709,775 | 1,128,382 |
Sector | Broad Market / Factor | Health |
52-Week High | $72.25 | $277.88 |
52-Week Low | $27.09 | $182.82 |
Typical Hold Time | 15 Days | 51 Days |
Enterprise Value | — | $31.14B |
Dividend Yield | — | 1.17% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →